3 results
Approved WMORecruiting
In 2013 the Boston Scientific VERCISE System has obtained regulatory approval for use in the European Union, CE mark was granted for the treatment of intractable primary and secondary dystonia.The objective of the study is to compile characteristics…
Approved WMORecruiting
1. Assess the effect of Ru-106 brachytherapy applicators on tumor dimensions. 2. Assess the value of DWI and PWI as an early predictor of therapy response after Ru-106 brachytherapy in UM.
Approved WMOCompleted
Primary Objective: - To investigate the effectiveness of the ProMIO lifestyle intervention (targeting protein intake and exercise behavior) on physical functioning in older adults from ethnic minorities (Turkish, Moroccan and Surinamese). Secondary…